{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityComment":"A hierarchical testing procedure was used to control the overall type I error. Testing was then performed sequentially in order the outcome measure are reported and continued when previous outcome measure was statistically significant at two-sided 0.05. Only the primary and the first 4 secondary outcome measures were included in the procedure.","nonInferiorityType":"SUPERIORITY","pValue":"0.0003","pValueComment":"Cochran-Mantel-Haenszel test stratified by ECOG performance status, time from AR-targeted agent initiation to progression, timing of AR-targeted agent as specified at the time of randomization. Significance threshold = 0.05.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.4","upperLimit":"45.1","value":"36.3"},{"groupId":"OG001","lowerLimit":"7.6","upperLimit":"21.0","value":"14.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"PSA response was defined as \\>= 50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Cabazitaxel 25 mg/m\\^2 IV infusion for over 1 hour on Day 1 of each 3 week treatment cycle in combination with Prednisone 10 mg orally once daily and primary prophylactic G-CSF as per investigator decision, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 22 weeks).","id":"OG000","title":"Cabazitaxel"},{"description":"Participants received either abiraterone acetate 1000 mg orally once daily from Day 1 to Day 21 of each 3 week treatment cycle in combination with prednisone 5 mg orally twice daily; or enzalutamide 160 mg orally once daily continuously from Day 1 to Day 21 of each 3 week treatment cycle, until radiographic disease progression, unacceptable toxicity, or participant's refusal of further study treatment (median duration = 12.5 weeks).","id":"OG001","title":"Abiraterone Acetate or Enzalutamide"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on subset of ITT population (any participant who had been allocated to a randomized treatment, analyzed according to group allocated) with PSA level \\>2 ng/mL at baseline, and with at least two post-baseline assessments before any further anti-cancer therapy for specified outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline up to PSA response, death due to any cause or data cut-off date whichever comes first (maximum duration: up to 141 weeks)","title":"Percentage of Participants With Prostate Specific Antigen (PSA) Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}